Scarica l'app Stockscreener
135.20
4.86%
6.27
Dopo l'orario di chiusura:
135.25
0.05
+0.04%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BIIB Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$128.93
Aprire:
$129.62
Volume 24 ore:
1.52M
Relative Volume:
1.04
Capitalizzazione di mercato:
$19.82B
Reddito:
$9.82B
Utile/perdita netta:
$1.48B
Rapporto P/E:
13.35
EPS:
10.13
Flusso di cassa netto:
$2.30B
1 W Prestazione:
+4.53%
1M Prestazione:
+0.74%
6M Prestazione:
-2.35%
1 anno Prestazione:
-33.74%
Intervallo 1D:
$129.40
$135.38
Intervallo di 1 settimana:
$127.00
$135.38
Portata 52W:
$110.03
$207.59
Biogen Inc Stock (BIIB) Company Profile
Nome
Biogen Inc
Settore
Industria
Telefono
(781) 464-2000
Indirizzo
225 BINNEY STREET, CAMBRIDGE, MA
Confronta BIIB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
135.20 | 18.77B | 9.82B | 1.48B | 2.30B | 10.13 |
|
LLY
Lilly Eli Co
|
660.49 | 569.45B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
174.42 | 418.62B | 90.63B | 22.66B | 16.40B | 9.35 |
|
ABBV
Abbvie Inc
|
201.47 | 350.91B | 58.33B | 3.76B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
121.20 | 229.50B | 55.19B | 13.65B | 16.81B | 6.86 |
|
MRK
Merck Co Inc
|
82.71 | 199.90B | 63.62B | 16.41B | 14.72B | 6.49 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-21 | Ripresa | Truist | Hold |
| 2025-04-28 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-04-04 | Downgrade | Argus | Buy → Hold |
| 2025-02-11 | Iniziato | Bernstein | Mkt Perform |
| 2025-01-02 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Downgrade | Stifel | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-12-09 | Downgrade | Jefferies | Buy → Hold |
| 2024-11-18 | Downgrade | Needham | Buy → Hold |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-10-31 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-02-14 | Reiterato | Needham | Buy |
| 2024-02-14 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Downgrade | UBS | Buy → Neutral |
| 2023-12-20 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Iniziato | HSBC Securities | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Outperform |
| 2023-07-24 | Reiterato | UBS | Buy |
| 2023-05-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-04-17 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-10-13 | Aggiornamento | Stifel | Hold → Buy |
| 2022-10-07 | Aggiornamento | Argus | Hold → Buy |
| 2022-09-28 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Aggiornamento | Mizuho | Neutral → Buy |
| 2022-09-28 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Downgrade | Stifel | Buy → Hold |
| 2022-03-03 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Reiterato | Barclays | Equal Weight |
| 2022-02-04 | Reiterato | BofA Securities | Neutral |
| 2022-02-04 | Reiterato | Cowen | Outperform |
| 2022-02-04 | Reiterato | Morgan Stanley | Overweight |
| 2022-02-04 | Reiterato | Needham | Buy |
| 2022-02-04 | Reiterato | Oppenheimer | Outperform |
| 2022-02-04 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Reiterato | Robert W. Baird | Neutral |
| 2022-02-04 | Reiterato | Wedbush | Neutral |
| 2022-02-04 | Reiterato | Wells Fargo | Equal Weight |
| 2022-02-04 | Reiterato | Wolfe Research | Peer Perform |
| 2022-01-13 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-01-12 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Ripresa | Raymond James | Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-12-06 | Iniziato | Goldman | Neutral |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2021-06-18 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Reiterato | Truist | Buy |
| 2021-06-11 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Aggiornamento | UBS | Neutral → Buy |
| 2021-06-08 | Aggiornamento | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Reiterato | Barclays | Equal Weight |
| 2021-06-08 | Aggiornamento | Citigroup | Sell → Neutral |
| 2021-06-08 | Reiterato | H.C. Wainwright | Buy |
| 2021-06-08 | Reiterato | Jefferies | Buy |
| 2021-06-08 | Reiterato | Morgan Stanley | Overweight |
| 2021-06-08 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Reiterato | Stifel | Buy |
| 2021-06-08 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2021-06-07 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Downgrade | DZ Bank | Buy → Hold |
| 2021-01-29 | Aggiornamento | Stifel | Hold → Buy |
| 2020-11-10 | Aggiornamento | DZ Bank | Hold → Buy |
| 2020-11-09 | Downgrade | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Downgrade | Cowen | Outperform → Market Perform |
| 2020-11-09 | Reiterato | H.C. Wainwright | Buy |
| 2020-11-04 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-11-04 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-07-27 | Aggiornamento | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Downgrade | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Downgrade | Citigroup | Neutral → Sell |
| 2020-04-23 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-01-27 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Downgrade | Robert W. Baird | Neutral → Underperform |
Mostra tutto
Biogen Inc Borsa (BIIB) Ultime notizie
Why Is Biogen Stock Climbing Wednesday?Biogen (NASDAQ:BIIB) - Benzinga
Biogen’s Felzartamab Trial: A Potential Game-Changer for Kidney Transplant Treatments - TipRanks
Rituxan Market Size to 2025: Emerging Demands, Trends, - openPR.com
Biogen Asserts No Obligation to Pay $122M in Intellectual Property Royalties Following Mistrial - USA Herald
5 Revealing Analyst Questions From Biogen’s Q2 Earnings Call - Yahoo Finance
Biogen Inc. (NASDAQ:BIIB) Shares Purchased by Motley Fool Asset Management LLC - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Shares Purchased by Invesco Ltd. - MarketBeat
Mizuho Securities USA LLC Reduces Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Given Average Rating of "Hold" by Analysts - MarketBeat
Mitsubishi UFJ Asset Management Co. Ltd. Acquires 27,734 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
LPL Financial LLC Grows Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Aigen Investment Management LP Buys Shares of 14,365 Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Ontario Teachers Pension Plan Board Buys Shares of 10,849 Biogen Inc. (NASDAQ:BIIB) - MarketBeat
[Latest] US Personalized Medicine Market Size/Share Worth USD 252.93 Billion by 2034 at a 17.32% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
Biogen Says It Owes Nothing After $122M IP Royalties Mistrial - Law360
Sector Update: Health Care - MarketScreener
Biogen CEO Sees Potential in Combining Alzheimer's, Obesity Drugs - MarketScreener
Biogen’s PREVAIL Study: A New Hope for IgA Nephropathy Treatment? - TipRanks
Biogen Sees Potential in Combining Alzheimer’s and Obesity Drugs - Bloomberg.com
Entropy Technologies LP Sells 17,087 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
National Bank of Canada FI Has $27.58 Million Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Charles Schwab Investment Management Inc. Buys 47,956 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Wolfe Research Issues Negative Estimate for Biogen Earnings - MarketBeat
Headlands Technologies LLC Cuts Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen’s Litifilimab Study: A Potential Game-Changer for Lupus Treatment - TipRanks
Biogen Faces Growing Pains Even As Its Pipeline Progresses - Finimize
FDA Action Alert: Biogen/Eisai, Sanofi, Ionis and More - BioSpace
Biogen, Stoke dose first patient in phase 3 Dravet syndrome trial - Investing.com Australia
Biogen and Stoke Therapeutics Announce First Patient Dosed - GlobeNewswire
Breakthrough Dravet Syndrome Drug Could Transform Treatment: Phase 3 Trial Launches - Stock Titan
Deutsche Bank AG Sells 228,518 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
White Lighthouse Investment Management Inc. Takes $291,000 Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen to invest additional $2B in North Carolina’s Research Triangle Park - MSN
Biogen Inc. (NASDAQ:BIIB) Shares Sold by Primecap Management Co. CA - MarketBeat
iA Global Asset Management Inc. Buys 2,636 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Can Biogen Inc. be recession proofSmart Allocation Stock Ideas - thegnnews.com
Biogen Inc. (NASDAQ:BIIB) Stock Holdings Raised by Natixis Advisors LLC - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Increases Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Koss Olinger Consulting LLC Acquires New Shares in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Will Biogen’s (BIIB) New Lecanemab Data and Earnings Shift Its Alzheimer’s Growth Narrative? - simplywall.st
Vanguard Group Inc. Buys 283,964 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Bank of Nova Scotia Sells 4,241 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Eli Lilly’s obesity pill data; This week’s Q2 highlights; Biogen’s latest reinvention; and more - Endpoints News
J. Safra Sarasin Holding AG Decreases Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen’s Innovative Approach to SMA Treatment: ThecaFlex DRx™ System Study Update - TipRanks
Biogen’s PIERRE-PK Study: A New Approach to Nusinersen Delivery in SMA - TipRanks
Acute Ischemic Stroke Pipeline 2025: Latest FDA Approvals, - openPR.com
FY2025 EPS Estimates for Biogen Lifted by Cantor Fitzgerald - MarketBeat
Arkadios Wealth Advisors Purchases Shares of 3,354 Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Research Analysts Offer Predictions for Biogen Q3 Earnings - MarketBeat
Eli Lilly And Biogen (And Eisai): Muddying The Waters In Alzheimer's Disease - Seeking Alpha
Biogen Inc Azioni (BIIB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):